Vanessa Carle PhD
Principal
Starting a new era in rheumatoid arthritis treatment
Elevara Medicines was founded to address a fundamental problem in rheumatoid arthritis (RA) where patients fail to achieve disease remission through immune targeted approaches. Proliferation and activation of fibroblast-like synoviocytes (FLS) is a central part of RA pathobiology and research over the last 20 years has shown these cells are direct contributors to the disease rather than innocent bystanders. By specifically targeting these cells, Elevara Medicines aims to break the efficacy ceiling patients experience with existing immunosuppressive drugs.
We believe ELV001 could have a fundamental impact on RA patients who fail to achieve disease remission through immune targeted approaches. This $70 million financing provides us with the resources to rapidly advance ELV001 through Phase 2 and to expand into other chronic inflammatory indications.Emma Tinsley
CEO
$70 million
Series A financing
Forbion team
Gijs van den Brink MD, PhD
Operating Partner
Roberto Hofmann PhD
Analyst
Gilles van Tienderen PhD
Associate